These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 31535280)

  • 1. The Use of Risk-Sharing Contracts in Healthcare: Theoretical and Empirical Assessments.
    Antonanzas F; Juárez-Castelló C; Lorente R; Rodríguez-Ibeas R
    Pharmacoeconomics; 2019 Dec; 37(12):1469-1483. PubMed ID: 31535280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of two pharmaceutical risk-sharing agreements on pricing, promotion, and net health benefits.
    Zaric GS; Xie B
    Value Health; 2009; 12(5):838-45. PubMed ID: 19490563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmaceutical Products and Their Value: Lessons Learned and the Path Ahead.
    Kaltenboeck A
    Value Health; 2020 Apr; 23(4):421-424. PubMed ID: 32327158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The simple economics of risk-sharing agreements between the NHS and the pharmaceutical industry.
    Barros PP
    Health Econ; 2011 Apr; 20(4):461-70. PubMed ID: 21394816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Should health authorities offer risk-sharing contracts to pharmaceutical firms? A theoretical approach.
    Antonanzas F; Juarez-Castello C; Rodriguez-Ibeas R
    Health Econ Policy Law; 2011 Jul; 6(3):391-403. PubMed ID: 21338542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can't get no satisfaction? Will pay for performance help?: toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products.
    Towse A; Garrison LP
    Pharmacoeconomics; 2010; 28(2):93-102. PubMed ID: 20085386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Value-Based Pharmaceutical Contracts: Value for Whom?
    Kannarkat JT; Good CB; Parekh N
    Value Health; 2020 Feb; 23(2):154-156. PubMed ID: 32113619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance-based risk-sharing agreements in renal care: current experience and future prospects.
    Drummond M; Federici C; Busink E; Apel C; Kendzia D; Brouwer W
    Expert Rev Pharmacoecon Outcomes Res; 2021 Apr; 21(2):197-209. PubMed ID: 33439090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implementation of risk-sharing contracts as perceived by Spanish hospital pharmacists.
    Lorente R; Antonanzas F; Rodriguez-Ibeas R
    Health Econ Rev; 2019 Jul; 9(1):25. PubMed ID: 31317339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of a pharmaceutical risk-sharing agreement when patients are screened for the probability of success.
    Mahjoub R; Ødegaard F; Zaric GS
    Health Econ; 2018 Jan; 27(1):e15-e25. PubMed ID: 28627808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Innovative agreements with the pharmaceutical industry: "pay for performance"].
    Badia X; Prior M
    Farm Hosp; 2010; 34(2):53-5. PubMed ID: 20207566
    [No Abstract]   [Full Text] [Related]  

  • 13. Risk-sharing arrangements that link payment for drugs to health outcomes are proving hard to implement.
    Neumann PJ; Chambers JD; Simon F; Meckley LM
    Health Aff (Millwood); 2011 Dec; 30(12):2329-37. PubMed ID: 22147861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Option pricing: a flexible tool to disseminate shared savings contracts.
    Friedberg MW; Buendia AM; Lauderdale KE; Hussey PS
    Am J Manag Care; 2013 Aug; 19(8):e285-92. PubMed ID: 24125491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Private sector risk-sharing agreements in the United States: trends, barriers, and prospects.
    Garrison LP; Carlson JJ; Bajaj PS; Towse A; Neumann PJ; Sullivan SD; Westrich K; Dubois RW
    Am J Manag Care; 2015 Sep; 21(9):632-40. PubMed ID: 26618366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Financial risk-sharing in updating the National List of Health Services in Israel: stakeholders' perceived interests.
    Hammerman A; Feder-Bubis P; Greenberg D
    Value Health; 2012; 15(5):737-42. PubMed ID: 22867784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Risk sharing contracts in the national health care system: Perceptions of health care professionals].
    Rojas García P; Antoñanzas Villar F
    Rev Esp Salud Publica; 2018 Jul; 92():. PubMed ID: 29961752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Risk-sharing agreements: choice of study design and assessment criteria].
    Launois R; Ethgen O
    Ann Pharm Fr; 2013 Sep; 71(5):346-57. PubMed ID: 24075705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-price competition in NHS secondary care contracting: empirical results.
    Gray K; Bailey MF
    J Health Organ Manag; 2008; 22(5):480-95. PubMed ID: 18959300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. National reimbursement listing determinants of new cancer drugs: a retrospective analysis of 58 cancer treatment appraisals in 2007-2016 in South Korea.
    Kim ES; Kim JA; Lee EK
    Expert Rev Pharmacoecon Outcomes Res; 2017 Aug; 17(4):401-409. PubMed ID: 28010146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.